Study of docetaxel and SX-682 for head and neck, salivary gland, and prostate cancers
Treatments studied
Part of Cancer, Ear, nose & throat, Kidney & urinary, Lungs & breathing, Mouth & dental clinical trials.
This trial combines two drugs—docetaxel (a standard chemotherapy) and SX-682 (an experimental drug that may help the immune system fight cancer)—to see if they work better together for people with certain advanced cancers that have spread or come back. It is for patients with head and neck squamous cell cancer, salivary gland cancer, or advanced prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have one of these cancers that has spread or come back: head and neck, salivary gland, or advanced prostate cancer.
- You are generally well enough to be up and about for at least half the day (ECOG performance status 0-2).
- Your blood counts, kidney function, and liver function are within acceptable ranges (your doctor will check).
- You agree to use effective birth control if you or your partner can become pregnant, and you won't donate sperm or eggs for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
This trial tests a combination of three medicines (SYS6002, JMT101, and Enlonstobart) for people with head and neck cancer that has come back or spread and cannot be removed by surgery or radiation. The goal is to see if this treatment helps shrink tumors or slow the disease.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new drug called OCT-598, alone or with chemotherapy, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.